ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Abstract Number: OC 56.4

F8 Genetic Variants Associated with Inhibitor Development in a Multiethnic Population of Non-severe Hemophilia A

M.Y. Lim^1,1, K. Lee², N.S Key²
Abstract Number: PB1124

Factor VIII and Prothrombin Time during Induction Therapy Correlate with Response to Treatment in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients

J. Vieira¹, A. Vagos Mata¹, I. Paulos Mesquita¹, S. Durão¹, H. Martins¹, A. Rodrigues¹, A. Garção¹, Á. Beleza¹, J. Raposo¹, G. Esteves¹
Abstract Number: OC 55.3

Factor VIII Inhibitors: Effects of Mutation and FVIII Antigen Revisited

S. Kuldanek¹, D. Thornhill¹, A. Tran¹, N. Briones¹, C. Baird¹, L. Jacobson¹, B. Warren¹, M. Manco-Johnson¹
Abstract Number: PB1096

Factor VIIIc Predicts Venous Thromboembolism in Gynecological Cancer Patients

E. Ibrahim^1,2, S. O'Toole^1,3,4, M. Ward^4,3, F. Abu Saadeh^1,2, L. Norris^1,3
Abstract Number: PB0697

Factor XI Deficiency in Pregnant Women: A Genotype to Phenotype Correlation and Analysis

G. Sacchi de Camargo Correia¹, S. Rajeeve², L. Cytryn¹
Abstract Number: PB0044

Factor XIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) Suppresses Plasma Clot Formation and Reduces Resistance to Fibrinolysis in vitro

L.A. Holle¹, J.M. Luettgen², A.S. Wolberg¹
Abstract Number: PB1144

FACTOR XII 46 C/T Gene Polymorphism as a Possible Risk Factor for Late-onset Venous Thromboembolism in Patients from the North-Western Russia

A. Chechulova¹, S. Kapustin², V. Soroka¹, V. Soldatenkov², L. Papayan², M. Galchenko³
Abstract Number: OC 22.3

Factor XIII Increases Cerebral Infarct Size by Promoting Thrombus Stabilization and Resistance to Revascularization Treatments in Ischemic Stroke

J. Marta-Enguita¹, F. Machado¹, M. Navarro-Oviedo¹, I. Esquisabel¹, C. Roncal^1,2, J.-A. Páramo^1,2,3, R. Muñoz⁴, J. Orbe^1,2
Abstract Number: PB0800

Factors, Determining Thrombus Recanalization in Children with Different Blood Disorders

P.A Zharkov¹, D.A Evstratov¹, K.A Voronin¹, D.V Fedorova¹, A.V Pshonkin¹
Abstract Number: PB0718

Familial Multiple Coagulation Factor Deficiencies (FMCFDs); A Rare Case of Combined Deficiency of Factor V and Factor VIII (F5F8D)

J. Rigano¹
Abstract Number: PB0827

Fatigue in Chronic Immune Thrombocytopenia Patients: Validation of the Checklist Individual Strength and Comparison to Other Chronically Ill Populations

W.E.M. van Dijk¹, I.A.R. Kuijlaars¹, M.H. Suijker², K.P.M. van Galen¹, R.E.G. Schutgens¹
Abstract Number: PB0626

Feasibility of Integrating PROBE (Patient Reported Outcomes, Burdens and Experiences) into a Clinical Care Pathway to Facilitate Transformation to a Value-based Health Care Model in Hemophilia

S. Jackson^1,2, B. Sheridan², D. Gue³, S. Lyons³, R. Waines³, T. Ireland³, D. Pete⁴, A. Iorio^5,4, L. Walsh⁴, M. Skinner⁶, F. Germini^7,8
Abstract Number: PB0540

Feasibility of Measuring through PROMIS Computer Adaptive Tests (CATs) and Short Forms (SFs) in Haemophilia – Preliminary Data

I.A. Kuijlaars¹, L. Teela², J.J. Muis^2,3, E.S. van Hoorn⁴, L. van Vulpen⁵, M. Timmer⁵, M. Coppens⁶, S.C. Gouw^3,7, M. Peters³, M.J. Kruip⁸, M.H. Cnossen⁹, L. Haverman², K. Fischer⁵
Abstract Number: OC 47.4

Features of Aspirin-resistant Biomechanical Platelet Activation in Fibromuscular Dysplasia

R. Bhandari¹, S. Shim¹, M. Godwin¹, A. Aggarwal¹, N. Fendrikova-Mahlay¹, S. Hazen¹, A.P. Owens², A. ElBadawi³, S. Cameron¹
Abstract Number: PB0318

Features of the Coagulation Potential of Blood in Patients with Endometriosis

I. Vasilenko^1,2, R. Lifenko³, S. Gasparyan⁴, Z. Kardashova¹, E. Rusanova¹
Abstract Number: PB0145

Fibrin Clot Characteristics and Anticoagulant Response in a SARS-CoV-2 Infected Endothelial Cell Model

C. McCafferty¹, L. Lee², T. Cai¹, S. Praporski¹, V. Karlaftis¹, C. Attard¹, S. Van Den Helm¹, N. Letunica¹, J. Stolper¹, D. Elliott¹, K. Subbarao^3,2, P. Monagle^4,5,1, V. Ignjatovic^1,4
Abstract Number: PB0139

Fibrinogen Adsorption on Hemofilter Membranes Associates with Severe COVID-19 and Renal Replacement Therapy Circuit Failure

D. Choi¹, F. Liu², A. Borczuk³
Abstract Number: PB0235

Fibrinogen and D-dimer Are Significantly Associated with Severity of COVID-19 Disease

M. El Horri¹, S.N.E. Touati¹, I. Khachaa¹, A. Chikh Khelifa¹, A. Berrah¹, L. Benmahdi¹, S.E. Belakehal¹
Abstract Number: PB0707

Fibrinogen Austin (Aα17Gly→Cys and Aα381Ser→Phe); Identification of a Novel Fibrinogen Mutation Causing Dysfibrinogenaemia

J. Rigano¹
Abstract Number: PB0400

Fibrinogen B Arg448Lys and Factor XIII Val34Leu Polymorphisms Are Associated with Prothrombotic Fibrin Clot Properties in Patients with Acute Pulmonary Embolism

A. Klajmon¹, J. Chmiel², M. Ząbczyk^2,1, J. Natorska^2,1, A. Undas^2,1
Abstract Number: PB0735

Fibrinogen Binding to Macrophages Attenuates Antiviral Responses to dsRNA

D. Martinez¹, M.J. Flick¹, S. Antoniak¹
Abstract Number: PB0416

Fibrinolytic Disorders as Cause of Bleeding in Patients with an Increased Bleeding Tendency

L. Valke^1,2, D. Meijer³, L. Nieuwenhuizen^2,4, B. Laros-van Gorkom^1,2, N. Blijlevens¹, W. Van Heerde^2,5, S. Schols^1,2
Abstract Number: OC 46.2

Fibrinolytic Shutdown Is Associated with Death, Mild Lung Injury and a New VV ECMO Requirement after Cardiac Surgery; A Single Center Case-control Study of 742 Patients

S. Wickers¹, N. Clendenen²
Abstract Number: PB0521

Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors

V. Jiménez-Yuste¹, F. Peyvandi², R. Klamroth³, G. Castaman⁴, C. Shanmukhaiah⁵, S. Rangarajan⁶, J. García Chavez⁷, R. Martinez⁸, G. Kenet⁹, H. Alzahrani¹⁰, S. Robson¹¹, C. Schmitt¹¹, A. Kiialainen¹¹, O. Meier¹¹, M. Ozelo¹²
Abstract Number: PB1232

Final Results (765 Answers) of the Brazilian National Survey in Thromboprophylaxis for Varicose Vein Surgery

A.J. Ribeiro¹, M.A. Marques², F.L. Erzinger³, A. Ribeiro⁴.
Abstract Number: PB0522

Final Results of ReITIrate – A Prospective Study of Rescue Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc (rFVIIIFc) in Patients who Have Failed Previous ITI Attempts

C. Königs¹, S. Meeks², M. Löfqvist³, J. Dumont⁴, L. Leickt³, S. Nayak³, S. Lethagen³
Abstract Number: PB0945

Finding the Balance between Bleeding Risk and Thromboembolic Risk: A Case Report

B. Merchan Muñoz¹, S. Herrero Martín¹, M.I. Nuevo López¹, M. Mora Argumánez¹
Abstract Number: PB0097

First Case of Wunderlich Syndrome under Apixaban – Case Report

T. Quaresma¹, S. Maltês², C. Carvalho Gouveia³, D.J. Canudo⁴, M. Rebelo⁵, F. Serrazina⁶, M.M. Deveza¹, M. Galvão¹
Abstract Number: PB0570

First Interim Analysis from the Observational HEM-POWR Study Evaluating Effectiveness and Safety of Real-world Treatment with Damoctocog Alfa Pegol in Previously Treated Patients with Hemophilia A

M. Reding¹, M. Teresa Alvarez Román², M. Sanabria³, G. Castaman⁴, M. Janbain⁵, T. Matsushita⁶, K. Meijer⁷, K. Schmidt⁸, J. Oldenburg⁹
Abstract Number: OC 08.1

First Interim Analysis of a 24-month French, Multicentre, Prospective, Non-interventional Study Evaluating the Real-world Usage and Effectiveness of the Extended Half-life Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B (B-SURE)

H. Chambost¹, A. Rauch², Y. Repesse³, S. Claeyssens⁴, S. Castet⁵, R. d'Oiron⁶, E. Santagostino⁷, C. Martinez⁸
Abstract Number: PB0526

Fitusiran Population Pharmacokinetic and Pharmacodynamic (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme

P. Bhagunde¹, S. Ge¹, S. Iqbal², B. Mei², S. Andersson², V. Kanamaluru¹, Q. Lu¹
Abstract Number: OC 26.3

Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B

W. Miesbach¹, K. Meijer², M. Coppens³, P. Kampmann⁴, R. Klamroth⁵, R. Schutgens⁶, G. Castaman⁷, E.K Sawyer⁸, F.WG Leebeek⁹
Abstract Number: PB0121

Fixed-dose 1500-unit 4F-PCC for Factor Xa inhibitor Reversal in Spontaneous or Traumatic Intracranial Hemorrhage

S. Lujan¹, C. Rodriguez¹, M. Mason¹, L. Anselmo¹, T. Goot¹, A. Burnett¹
Abstract Number: PB0006

Flowcytometric Assay of Platelet-derived Microparticles and the Dual Anti-platelet Therapy in Egyptian Patients with Ischemic Heart Disease, a Promising Indicator

N. Farouqe¹, M. Wahba¹, A. Saad¹, R. El-Gamal¹, Y. Elsakhawy¹, M. Farouk²
Abstract Number: OC 05.2

Fluorescence Correlation Spectroscopy Provides New Insights into the Mechanism of Prothrombin Recognition by the Prothrombinase Complex

M. Chinnaraj¹, N. Pozzi¹, E. Di Cera¹
Abstract Number: OC 11.4

Force-Independent Cleavage of Talin by Calpain Promotes Platelet-mediated Fibrin Clot Contraction

K.P.Y. Fong¹, R.I. Litvinov¹, O. Kim¹, K. Molnar², J.A. Wells², J.W. Weisel¹, W.F. DeGrado², J.S. Bennett¹
Abstract Number: PB0346

Frequency and Clinical Significance of Different Types of Calreticulin (CALR) Mutations in Myeloproliferative Neoplasms (MPNs): A Cohort of Patients from Pakistan

R. Ahmed¹, M. Rashid², U. Zaidi², T. Shmasi²
Abstract Number: PB0457

Frequency of Dosing and Presence of Endogenous VWF Influences FVIII Inhibitor Development

M. Cormier¹, K. Nesbitt¹, P. Batty¹, C. Hough¹, D. Lillicrap¹
Abstract Number: PB1171

Frequency of Hereditary Thrombophilia in Venous Thromboembolic Disease

K. Mendi¹
Abstract Number: PB0885

Frequent Platelet Dysfunction and Fibrinolysis in Patients with Intracerebral Hemorrhage

P. Lindholm¹, H. Kwaan², I. Weiss², A. Naidech³
Abstract Number: OC 16.1

From Coagulation to Angiogenesis: Extra-coagulative Role of FVIII

C. Olgasi¹, A. Cucci¹, C. Borsotti¹, G. Walker¹, I. Molineris², F. Anselmi², S. Assanelli¹, C. Sgromo¹, S. Oliviero², A. Follenzi¹
Abstract Number: PB0649

From Stroke Treatment, through a Tongue Bite, until Intensive Care Unit: The Challenge of Antithrombotic Treatment in People with Haemophilia. A Case Report

S. Teixeira¹, I. Machado¹, D. Gonçalves¹, J.P. Silva², S. Fernandes¹, M. Lopes¹, M. Carvalho¹, D. Aranda¹, C. Koch¹
Abstract Number: LPB0109

Full Automation of the Bethesda Assay

T. Siegemund¹, A. Siegemund¹, H. Bönigk¹
Abstract Number: PB0666

Functional Transitory Anti-emicizumab Antibody Creating Bleeding Episodes

F. Peyvandi¹, S. Braham², R. Gualtierotti¹, S. Arcudi³, L. Schiavone², C. Novembrino², C. Valsecchi²
Abstract Number: PB0380

FVIII Stability, the Limiting Factor in Chromogenic Fix Kits?

A. Evenepoel¹, C. Gavard¹, S. Desmet¹, V. Deneys¹, M.-A. van Dievoet¹
Abstract Number: PB0076

FXI-independent Pathways of Contact Activation: Analysis of Activated Partial Thromboplastin Time (aPTT) Data Using Mathematical Modelling

A. Rezvani-Sharif¹, S. Rauth¹, J. Arthur¹, P. Niebl², S. Dower¹, C. Panousis¹, I. Muir¹
Abstract Number: LPB0110

FXIIIa-mediated Fibrin γ-chain Crosslinks Are Critical for Fibrin Fiber Stiffness and Resistance to Rupture

T. Feller¹, C. Duval¹, S.D.A. Connell², R.A.S. Ariёns¹

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z